| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.42B | 2.58B | 2.92B | 3.13B | 2.88B | 1.96B |
| Gross Profit | 130.43M | 172.05M | 332.96M | 329.61M | 458.81M | 234.65M |
| EBITDA | 214.15M | 260.67M | 406.97M | 412.42M | 564.65M | 351.78M |
| Net Income | 66.80M | 84.61M | 190.08M | 194.38M | 266.08M | 125.28M |
Balance Sheet | ||||||
| Total Assets | 2.15B | 2.02B | 2.10B | 1.87B | 1.84B | 1.76B |
| Cash, Cash Equivalents and Short-Term Investments | 752.79M | 702.10M | 797.81M | 535.47M | 425.06M | 367.10M |
| Total Debt | 41.73M | 28.14M | 28.04M | 28.36M | 124.29M | 319.40M |
| Total Liabilities | 293.92M | 211.98M | 334.04M | 248.69M | 361.52M | 524.98M |
| Stockholders Equity | 1.85B | 1.80B | 1.76B | 1.61B | 1.47B | 1.23B |
Cash Flow | ||||||
| Free Cash Flow | 13.66M | -68.89M | 302.42M | 261.12M | 271.56M | 134.97M |
| Operating Cash Flow | 266.98M | 119.76M | 372.77M | 306.18M | 350.37M | 312.88M |
| Investing Cash Flow | -247.93M | -171.00M | -62.89M | -36.38M | -48.25M | -169.90M |
| Financing Cash Flow | -22.46M | -50.99M | -53.16M | -159.45M | -238.97M | -203.52M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | HK$1.21B | 16.88 | 3.61% | 1.85% | -8.51% | -68.34% | |
59 Neutral | HK$2.36B | 132.95 | 2.59% | ― | 11.08% | 147.89% | |
57 Neutral | HK$2.78B | 3.69 | 13.87% | ― | 9.20% | 213.87% | |
54 Neutral | HK$1.22B | 18.94 | 2.46% | 3.73% | -5.29% | -32.47% | |
41 Neutral | €153.61M | -1.89 | -13.04% | ― | -17.15% | 30.94% | |
40 Underperform | HK$162.76M | -0.27 | -112.79% | ― | -22.72% | -212.73% |
Dongguang Chemical Ltd. reported its unaudited consolidated interim results for the six months ending June 30, 2025, showing a decrease in revenue and profit compared to the same period in 2024. The company’s revenue fell from RMB 1,337,234,000 to RMB 1,180,762,000, and profit decreased from RMB 89,795,000 to RMB 72,931,000. Despite these declines, the company managed to achieve a positive net gain in other income and a reduction in income tax expenses, which slightly mitigated the impact on its overall financial performance.
The most recent analyst rating on (HK:1702) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Dongguang Chemical Ltd. stock, see the HK:1702 Stock Forecast page.
Dongguang Chemical Ltd. has announced that its board of directors will meet on August 27, 2025, to review and approve the company’s unaudited consolidated financial statements for the first half of 2025. The board will also consider the payment of an interim dividend, which could have implications for the company’s financial strategy and shareholder returns.